IDX-184

IDX-184是一种抗病毒药物，开发用作 RNA聚合酶抑制剂来治疗丙型肝炎。Elfiky AA, Elshemey WM. IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study. Med Chem Res. 2016;25(5):1005-1008.  Elfiky AA. Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study. Med Chem. 2019;15(2):130-137.  尽管它在早期臨床試驗中显示出一定效果，但并未通过IIb期试验。Gentile I, Buonomo AR, Zappulo E, Borgia G. Discontinued drugs in 2012 - 2013: hepatitis C virus infection. Expert Opin Investig Drugs. 2015 Feb;24(2):239-51.  然而，该药物的研究仍在继续，并对一些新病毒（如茲卡病毒Elfiky AA. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J Med Virol. 2016 Dec;88(12):2044-2051.  Elfiky AA, Ismail AM. Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures. SAR QSAR Environ Res. 2018 May;29(5):409-418.  、MERSElfiky AA, Mahdy SM, Elshemey WM. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J Med Virol. 2017 Jun;89(6):1040-1047.  和SARS-CoV-2等冠状病毒Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020 May 1;248:117477.  Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020 Mar 25:117592.  ）显示出一定的药物活性。

 参考文献 

Category:抗病毒药物
Category:有机硫化合物